Exciting research in breast cancer
1.Olapani slowed the progression of BRCA mutations associated with breast cancer
In the field of breast cancer, from New York's memorial Sloan caitlin cancer center is a major researcher Mark e. Robson professor's report on the conference hakeem (Olaparib) with standard chemotherapy in BRCA mutations in breast cancer associated with the application of comparative results.
The study included 302 patients with metastatic hormone receptor positive/tri-negative (estrogen receptor negative, progesterone receptor negative, HER2 negative) with harmful BRCA mutations.
HER2 positive breast cancer patients are not included in this study because they already have a very effective targeting treatment.
All patients were randomly assigned to the olapani treatment group and the standard chemotherapeutic treatment group (capectamine, changchun riebin or airibrin), until the tumor progression or the patient had severe side effects.
The results showed that 60 percent of patients who received olapani's treatment had a smaller tumor reduction compared with 29 percent of those who underwent standard chemotherapy.
During the median follow-up period of about 14 months, the risk of tumor progression in patients treated with olapani decreased by 42 per cent.
The median non-progress survival (PFS) was in the olapani group for seven months and the standard chemotherapy group was 4.2 months.
After the tumor progressed, the researchers followed up with the patient to see how long the tumor had deteriorated again.
The length of the tumor's progress again was longer, and the olapani treatment group showed that, when olapani stopped working, the tumor did not become more aggressive.
But the study is not mature enough to determine whether orapani can translate treatment benefits into prolonged periods of total survival.
The most common side effects of olapani's treatment group were nausea and anemia, while low white blood cell counts, anemia, fatigue, and rashes were most common in standard chemotherapy groups.
The orapani treatment group had fewer side effects than the chemotherapy group, with 37% vs 50%.
Only 5 percent of patients stopped using olapani because of side effects.
Health-related quality of life was significantly better in the olapani treatment group.
Professor Mark e. Robson said: "with the BRCA mutations related to breast cancer, compared to a standard treatment for women it is PARP inhibitors improve prognosis of the first certificate. At the same time is exciting, ora panitan for has inherited, the BRCA mutations 3 negative breast cancer in women. This type of breast cancer treatment is very difficult and often occur in young women."
2.Abemaciclib prolongs the survival of breast cancer patients
The ASCO2017 MONARCH, announced at the annual meeting of two phase III clinical trial results show that for HR + / HER2 breast cancer patients, compared with fluorine d SiQun monotherapy, CDK4/6 inhibitors abemaciclib joint fluorine d SiQun treatment can make the patients had a 45% lower risk of disease progression or death.
In the MONARCH 2 experiment, 669 patients were randomly assigned to the abemaciclib group (n = 446, the group of fluorocarbons combined with abemaciclib) or the control group (n = 223, fluvistes and placebo).
Into the patient needs to meet during receiving neoadjuvant or adjuvant endocrine therapy, adjuvant endocrine therapy in the 12 months, or a line of endocrine therapy in metastatic tumors during disease progression, and transfer out lesions treated with chemotherapy or endocrine therapy in patients with more than 1 time.
The results showed that the average PFS of the abemaciclib group and the control group were 16.4 months and 9.3 months respectively.
The ORR in the Abemaciclib queue was 48.1%, with total remission rate (CR) at 3.5%.
The control group had no total relief.
The median reduction in the placebo group lasted 25.6 months, while the median duration of the fluorine group was not yet reached.
The total survival time (OS) data is not yet mature.
Abemaciclib group and the control group at all levels of the most common treatment-related adverse events (AEs) respectively, diarrhea (86.4% vs 24.7%), neutropenia (46.0% vs 4.0%), nausea (45.1% vs 22.9%), and fatigue strength (39.9% vs 26.9%).
In patients with breast cancer with HR + / HER2, the cdk4/6 inhibitor abemaciclib combined with fluorovesem-group therapy can significantly reduce the disease progression or death risk in patients with breast cancer.
It is understood that the trial of abemaciclib co-endocrine therapy as adjuvant therapy will be carried out in the second half of the year, namely, the trial of the monarchs phase III.
prev:Exciting research in the field of liver cancer(2017-07-03)
next:Exciting research in the field of gastrointestinal cancer(2017-07-04)